This activity is supported by a grant from AstraZeneca , Wilmington, Delaware.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008; 359: 2195-2207
- JUPITER clinical directions—polling results.N Engl J Med. 2009; 360: e14
- Expanding the orbit of primary prevention—moving beyond JUPITER.N Engl J Med. 2008; 359: 2280
- C-reactive protein and cardiovascular risk: more fuel to the fire.Lancet. 2010; 375: 95-96
- JUPITER and the world of stroke medicine.Lancet Neurol. 2009; 8: 129-131
- A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N Engl J Med. 2009; 360: 1851-1861
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.Lancet. 2010; 375: 132-140
- The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Am J Cardiol. 2004; 93: 136-141
- Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.N Engl J Med. 2005; 352: 29-38
- Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients.Am J Cardiol. 1995; 76: 98C-106C
- Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial.J Am Coll Cardiol. 2009; 54: 2358-2362
- Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk in Communities) study.J Am Coll Cardiol. 2009; 54: 2388-2395
- Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).(Accessed on March 18, 2010)
- Long-term follow-up of the West of Scotland Coronary Prevention Study.N Engl J Med. 2007; 357: 1477-1486
- Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, β-blockers, or statins.Gender Med. 2008; 5: 53-61
- The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: extended observations 2 years after trial closure.Eur Heart J. 2008; 29: 499-508
- Rosuvastatin in older patients with systolic heart failure.N Engl J Med. 2007; 357: 2248-2261
- Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.Circulation. 2009; 120: 2188-2196
- Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).Circulation. 2010; 121: 143-150
- The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it.Obesity. 2006; 14: 737-752
- Improvement in glucose control with lifestyle intervention reduces C-reactive protein in obese subjects with type 2 diabetes: the Look AHEAD study.Circulation. 2009; 120: S473-S474
Virani SS, Woodard L, Robinson C, Pietz KC, Urech TH, Ballantyne CM, Petersen LA. Has LDL cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) goal attainment improved 7 years after Adult Treatment Panel III (ATP III) guidelines were published? Circ Cardiovasc Qual Outcomes. In press.
Article Info
Footnotes
This discussion took place February 12, 2010.
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Inflammation and Atherothrombotic DiseaseAmerican Journal of CardiologyVol. 108Issue 8
- PreviewThe remarks of Paul Ridker, MD, in the recent “Editor's Roundtable”1 require comment. Ridker declares high-sensitivity C-reactive protein (hsCRP) to be a major risk factor for atherothrombotic disease (ATD). Dr. Ridker is in error in this statement. If hsCRP were a major ATD risk factor, then subjects with the highest levels of hsCRP should have the highest risk for ATD, and as Ridker himself has pointed out, natives of sub-Saharan Africa frequently have malaria, and those who do have malaria have extremely high levels of hsCRP but do not have ATD events to any significant degree.
- Full-Text
- Preview
